The effect of Coenzyme Q10 in depressed patients

Comparing the effect of coenzyme Q10 and placebo on the severity of depressive symptoms in the treatment of patients with (major) depression

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161204031229N5

Enrollment

Registered

2021-09-13

Start date

2021-09-01

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Major depressive disorder, single episode, unspecified

Interventions

Intervention 1: Intervention group: 200 mg coenzyme Q10 twice daily plus standard treatment of depression for 8 weeks. Intervention 2: Control group: Placebo plus standard treatment for depression for

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients between 18-65 years old Patients with diagnosed depression

Exclusion criteria

Exclusion criteria: Patients with mixed episodes of depression and manic or hypomanic phase Patients with severe disease Patients who administrated antidepressant agents during 1 month ago Patients who administrated any antioxidant agents or supplements during 1 month ago Pregnant patients

Design outcomes

Primary

Measure	Time frame
Depression severity. Timepoint: Before the intervention, at the 4th week of intervention, at the 8th week of intervention. Method of measurement: By beck inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzade Eshraghi

Iran University of Medical Sciences

eshraghi.a@iums.ac.ir+98 21 8670 2030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026